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Abstract
Objectives. Autoimmune polyglandular syndrome type-1 (APS-1) is
a monogenic recessive disorder characterised by multiple
endocrine abnormalities, chronic mucocutaneous candidiasis and
high titres of serum autoantibodies. To date, no curative
treatment is available; current therapies manage the symptoms
rather than treating the cause and have major side effects. APS-1
is caused by mutations in the autoimmune regulator (AIRE) gene.
AIRE mediates central tolerance by directing the ectopic
expression of tissue-specific antigens (TSAs) in medullary thymic
epithelial cells, causing the deletion of self-reactive thymocytes.
Therefore, loss-of-function mutations in AIRE result in a
multisystem autoimmune disease. Because of the monogenic
aetiology of APS-1 and availability of an APS-1 mouse model, we
have explored the option of restoring functional AIRE using
adeno-associated virus serotype 9 (AAV9). Methods. The efficacy
of AAV9-AIRE (AAV9 carrying AIRE cDNA) gene therapy was
assessed in an APS-1 mouse model. We performed intrathymic
injection of AAV9-AIRE into APS-1 mouse model using ultrasound
imaging technique to accurately locating the thymus. We
evaluated the efficiency of this approach alongside measures of
autoimmunity and histology of target tissues. Results. Intrathymic
injection of AAV9-AIRE demonstrated high transduction efficiency
and restored AIRE expression in the thymus. AIRE gene delivery
led to a significant increase in TSA expression, and importantly a
significant reduction of serum autoantibodies in treated versus
control mice, which fell to near-undetectable levels by 4 weeks
post-treatment. Furthermore, histological analysis of treated
animals showed near-normal tissue morphology with no
lymphocytic infiltrations, a hallmark of untreated Aire-deficient
mice. Conclusion. This study has demonstrated the feasibility of
AAV9-AIRE as a vehicle for gene therapy for APS-1.
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INTRODUCTION
Autoimmune polyglandular syndrome type 1
(APS-1) also known as autoimmune
polyendocrinopathy candidiasis ectodermal
dystrophy (APECED) is an incurable monogenic
autosomal recessive disorder1 classed as a primary
immunodeficiency disease (PID). It is characterised
by the manifestations of both endocrine and
nonendocrine organ destruction.1,2 Typically, the
initial presentation is with chronic mucocutaneous
candidiasis (CMC), followed by
hypoparathyroidism and then adrenal
insufficiency (Addison’s disease).1,2 Serum from
APS-1 patients was found to have high titres of
autoantibodies against multiple tissue-specific
antigens (TSAs).3 For instance, autoantibodies to
the adrenal glands were identified in APS-1
patients and autoantibodies to NLRP5 were
detected in almost 50% of APS-1 patients with
hypoparathyroidism and absent in patients
without hypoparathyroidism.4 Similarly,
autoantibodies to thyroid were detected in APS-1
patients with hypothyroid who were seropositive
to thyroglobulin (TG) and thyroid peroxidase
(TPO).5 Furthermore, autoantibodies against
CYP21A2, CYP17A1 and CYP11A1 were detected
in APS-1 patients with Addison’s disease.6,7
Autoimmune polyglandular syndrome type-1 is
caused by loss-of-function mutations in the
autoimmune regulator (AIRE) gene,8–10 resulting
in a dysfunctional or absent AIRE protein. AIRE
represents the first single-gene defect resulting in
a multisystem autoimmune disease.11 To date,
more than 100 APS-1 causing mutations have
been identified which vary from substitutions,
insertions and deletions to splice-site mutations.12–14
Several studies have demonstrated that AIRE/
Aire is expressed mainly by the thymus, in a
subpopulation of medullary thymic epithelial cells
(mTECs), AIRE+ mTECs.9,15–17 AIRE/Aire promotes
self-tolerance in the thymus by regulating the
promiscuous expression of a wide array of tissue-
specific antigens (TSAs).18 Several studies
demonstrated that TSA expression levels reflect
Aire expression pattern in a dose-dependent
manner.19–21 In APS-1 patients, dominant
inheritance of heterozygous missense mutations in
AIRE produces a reduced level of AIRE and is
characterised by a milder phenotype.22 Similarly,
G228W, the autosomal dominant mutation in
APS-1 patients, presents a mild phenotype
compared to patients with an autosomal recessive
mutation.23,24 The G228W-knock-in mouse model
partially expressed Aire-dependent TSAs with a
disease spectrum with milder autoimmune
phenotype.25 These findings suggest that precise
level of functional Aire protein is crucial for
efficient induction of TSA expression and thus
negative selection of T cells to avert
autoimmunity.
Studies using in vivo APS-1 mouse models have
significantly increased our knowledge of AIRE
function and APS-1-associated autoimmunity.26
The first animal model for APS-1 was engineered
in 2002; these Aire/ mice exhibited lymphocytic
infiltration and circulating serum autoantibodies
against specific structures of targeted organs.18,27
Aire/ mice have been used to elucidate the
function of Aire, and its primary action is to
promote promiscuous gene expression of TSAs
within mTECs and the clonal deletion of
autoreactive T cells.18
Gene-based delivery of AIRE could be an
efficient way of treating APS-1 patients because
the current treatment of APS-1 is challenging and
dependent on multiple therapeutic agents that
address individual manifestations, such as
hormone replacement therapy, antifungal agents
and immunosuppressive therapy for severe
features such as autoimmune hepatitis, interstitial
lung disease, enteropathy and malabsorption
associated with exocrine pancreatic
insufficiency.3,28 In an attempt to compensate for
Aire expression in athymic mice, cotransfer of one
thymic lobe from each Aire+/+ and Aire/ into
athymic mice did not prevent autoimmunity.29
However, when one thymic lobe from Aire/ and
4 thymic lobes from Aire+/+ were transferred into
athymic mice, autoimmune infiltrates were
reduced, suggesting a gene dose effect.29
Gene therapy offers a window of opportunity
to tackle monogenic disorders such as APS-1.
Multiple animal studies have been successfully
undertaken using viral vectors, providing
optimism for the future utility of viral gene
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delivery as a therapeutic strategy for various
conditions.30–32 Currently, the adeno-associated
(AAV)-based system is one of the most refined
and effective gene delivery systems for multiple
cell types. Several reports have shown that AAV
serotype 9 (AAV9) mediates efficient and
sustained transgene expression following systemic
administration in neonatal mice, which was
sufficient to extend survival in mouse models of
spinal muscular atrophy (SMA).31,33 Remarkable
safety and efficacy data were reported from 2
separate phase I/II clinical trials in haemophilia B
and SMA patients.34–36
This study elucidates the therapeutic potential
of AAV9-mediated AIRE gene replacement in
Aire/ mice. Because of the monogenic aetiology
of APS-1, we hypothesised that the thymic
compartment can be targeted to modulate
immune tolerance by using a gene therapy
approach to restore a functional copy of the AIRE
gene. Our study revealed that gene delivery using
AAV9 vectors (AAV9-AIRE) into mouse thymus led
to a profound amelioration of the APS-1
phenotype in Aire/ mice.
RESULTS
Characterisation of the Aire Null phenotype
in mice
As the onset of the disease could be a crucial step
in determining the efficiency of the treatment,
the histopathological phenotype of Aire/ mice
was performed prior to and early in the disease.
The tissues of two groups of 4- and 12-week-old
Aire/ and Aire+/+ littermates were analysed. No
observable lymphatic infiltrations were detected
in 4-week-old Aire/ mice in eyes, lung, liver,
stomach or reproductive organs, consistent with
previous studies.18,37–40 However, in 12-week-old
Aire/ mice, all mice (n = 4) exhibited infiltrates
in one or several organs including liver, lung,
stomach and testis. The latter showed also a
Leydig cell hyperplasia (LCH) morphology leading
to autoimmune gonadal atrophy (Figure 1a). No
observable infiltrations were detected in any
tissues in 12-week-old Aire+/+ mice (Figure 1b).
Construction and in vitro validation of
AAV9-AIRE
A plasmid harbouring a single-stranded AAV9
expression cassette carrying the wild-type human
AIRE complementary DNA (cDNA) [National
Centre for Biotechnology Information (NCBI)
accession number NM_000383.3] coding sequence
under the control of the cytomegalovirus (CMV)
promoter (AAV-AIRE) was generated
(Supplementary figure 1). We then transfected
human embryonic kidney (HEK) 293 cells, which
resulted in up-regulated expression of AIRE
protein as assessed by Western blot (Figure 2a).
After large-scale production of the AAV9-AIRE
viral vector, we evaluated its potency to express
AIRE by HEK293 cell transduction with 4.3 9 1010
and 4.3 9 1011 vector genomes (vg) per well
followed by Western blotting (Figure 2b). A
concentration of 4.38 9 1010 vg lL1 of AAV9-
AIRE yielded high AIRE expression level compared
to untransduced. In addition, higher expression of
AIRE was observed at a concentration of
4.38 9 1011 vg lL1. Densitometry analysis
confirmed this dose-dependent pattern of AIRE
expression, showing more than twofold increase
in AIRE expression with the higher dose at 5 days
after transduction as compared to transduced cells
with 4.38 9 1010 vg lL1 (Figure 2c).
AAV9-mediated AIRE expression in the
thymi of Aire/ mice AAV9-AIRE
To determine the optimal dose of AAV9-AIRE to
be used for our efficacy studies, a dose-dependent
experiment was carried out on Aire mice with the
doses of the virus listed in Table 1. Four groups of
mice were recruited: Aire+/+ mice were injected
with PBS (n = 5), Aire/ were injected with PBS
(n = 5), Aire/ mice were injected with AAV9-GFP
(n = 5), and Aire/ mice were injected with
AAV9-AIRE (n = 5), each mouse with a different
dose (Table 1). The total dose of 1.6 9 1010 vg
was well tolerated by the animal and gave the
best response in terms of clearance of circulating
autoantibodies and tissue infiltration in these
animals.
To examine the transduction efficiency of AAV9
in vivo, we injected Aire mice at 4 weeks old
(before the establishment of the disease) or
8 weeks old (after the establishment of the
disease) with AAV9 encoding green fluorescent
protein (GFP) (AAV9-GFP), AAV9-AIRE or PBS
intrathymically at a total dose of 1.6 9 1010 vg
per mouse. As expected, negative controls
represented by mice injected with PBS showed no
staining for Aire in the medulla as highlighted by
medulla marker K5 staining only (Figure 3a;
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n = 5). Targeting the medulla was a priority for
full therapeutic potential; therefore, expression at
this site was validated using AAV9-GFP. Mice
injected with AAV9-GFP led to widespread thymic
medulla transduction, as indicated by the
fluorescence intensity of GFP in the thymus
4 weeks postinjection (Figure 3b; n = 5). As
expected, AIRE was not detected in the thymus of
mice injected with AAV9-GFP (Figure 3c; n = 5). In
contrast, mice injected with AAV9-AIRE led to
AAV9-AIRE transduced mTECs resulting in AIRE
expression within cell nuclei in a punctate pattern
(Figure 3d; n = 5) similar to endogenous Aire in
wild-type littermates (Figure 3e; n = 5). Keratin 5
antibody was used as a surface marker to identify
mTECs41–43 (Figure 3a; n = 5).
AIRE gene replacement restores Aire-
dependent TSAs in the thymus
To quantify the restored AIRE at the mRNA level,
qPCR analysis (see Methods) was performed on
thymic lysates of all groups. Four weeks
postinjection, AAV9-mediated gene transfer
resulted in a significant increase (P ≤ 0.05) in AIRE
mRNA levels in thymic cells compared with PBS
and AAV9-GFP injections and a 1000-fold change
compared with endogenous levels in Aire/ mice
(Aire is expressed but not translated into
functional protein in these mice) (Figure 4a;
n = 3). To determine whether an increase in Aire-
dependent TSAs followed AIRE overexpression, we
tested a panel of well-established Aire-dependent
TSAs including Ccl1, IL-3, Ins2, Spt1, Apoa1 and
Reg1.29,44 Indeed, restoration of AIRE levels,
mediated by intrathymic AAV injection, resulted
in an elevation of expression of all 6 Aire-
dependent TSAs studied (Figure 4a; n = 3). A
significant increase was observed in both Ins2
(P < 0.0001) and Spt1 (P < 0.005) when compared
to PBS-treated Aire/ mice. There was also a
significant increase of Ins2 expression in the
thymus of AAV9-AIRE compared to control mice
including Aire/ mice and AAV9-GFP mice
(Figure 4a; n = 3). In contrast, none of the Aire-
independent genes including Cpox, Ncoa6 and
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Figure 1. Tissue lymphocytic infiltration of 12-week-old Aire/ mice. (a) Tissue section of stomach, testis and lung of 12-week-old Aire+/+ and
Aire/ mice was stained with haematoxylin and eosin (H&E). Lymphocyte infiltration of stomach, testis and lung of Aire/ mice is indicated by
arrows. Scale bar = stomach, 250 lm; testis, 250 lm; lung, 500 lm. (b) Summary of tissue infiltrate in Aire+/+ and Aire/ mice. In 4-week-old
mice, no tissue infiltration was observed in Aire+/+ or Aire/ mice. In 12-week-old mice, tissues with lymphocytic infiltration are highlighted for
each Aire/ mouse.
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Pplb showed significant changes in the level of
their expression between the 4 groups of mice
(Aire/, Aire+/+, Aire/AAV9-GFP and Aire/
AAV9-AIRE) (Figure 4b; n = 3). These data indicate
that modulation of AIRE in vivo can directly lead
to alterations in specific TSA levels and may have
the potential to affect the maintenance of central
tolerance.
To determine whether forced expression of
AIRE had maintained the self-tolerance in Aire/
mice, we analysed the presence of autoantibodies
in Aire/ mice sera using 4% PFA-fixed tissue
sections from healthy mice by indirect
immunofluorescence. In 8-week-old mice,
circulating autoantibodies against retina, lung,
stomach, testis and ovary were similar in Aire/
mice injected with PBS and Aire/ mice injected
with AAV9-GFP (Figure 5; n = 5). At 8 weeks,
serum autoantibodies were found against 1 or 2
tissues (stomach, lung, retina and ovary/testis) per
mouse. In Aire/ mice which were untreated
(n = 10), 60% exhibited autoimmunity against the
retina, ranging from a weak to a strong reaction.
In addition, autoantibodies against the
reproductive tissues, testis and ovary, were
present in 60% of Aire/ mice. Furthermore, 40%
of Aire/ mice control group displayed
autoreactivity against both lung and stomach. In
complete contrast, weak or almost undetectable
serum reactivity was observed in Aire+/+ mice
injected with PBS and Aire/ mice injected with
AAV9-AIRE (Figure 5; n = 5). These data suggest
that AAV9-AIRE significantly decreased circulating
autoantibodies from the sera of 8-week-old Aire/
AAV9-AIRE mice.
In the APS-1 mouse model, infiltrations show an
age-dependent pattern, ranging from none at
4 weeks to at least three or four tissues at
12 weeks.37 In keeping with this, at 8 weeks old,
retinal degeneration, damaged oocytes and LCH
morphology were detected in Aire/ mice and
AAV9-GFP-treated Aire/ mice (Figure 6; n = 5).
Furthermore, mild infiltrations were observed in
the lung, stomach and liver of the same mice
groups (Figure 6). In agreement with several
studies, the majority of Aire/ mice with tissues
targeted by serum autoantibodies are also
targeted by lymphocytic infiltrates.18,37 All Aire/
mice injected with AAV9-AIRE (n = 5) showed no
or very minimal tissue damage or infiltration in
the investigated tissues (Figure 6; n = 5),
suggesting that these mice were protected from
tissue-specific autoimmune reactions at this time
point. Correlation of serum autoantibodies and
infiltrations into retina, lung, stomach, pancreas
and ovary/testis tissues is summarised in Figure 7.
The latter showed strong correlation between the
presence of serum autoantibodies and tissue
infiltration. Mice treated with AAV9-AIRE showed
a trace or no circulating autoantibodies and
lymphatic tissue infiltration (Figure 7; n = 5).
AAV9-AIRE gene transfer in Aire-deficient
mice after disease onset
To determine whether there is rescue of the
phenotype in Aire-deficient mice alongside
Aire (59kD)
-acn (42kD)
Aire (59kD)
-acn (42kD)
(a)
(b)
Figure 2. Generation and in vitro validation of AAV9-AIRE. (a)
Western blot of AIRE expression 48 h after transfection of HEK293
cells with the pAAV-AIRE plasmid. AIRE levels were normalised to b-
actin levels. (b) Western blot of AIRE expression 5 days after
transduction of HEK293 cell AAV9-AIRE viral vector. AIRE levels were
normalised to b-actin levels.
Table 1. Concentrations of AAV9-AIRE and AAV9-GFP injected per
mouse
Dilution of the viral prep Amount of virus injected per mouse
1 8 9 1011 vg
1:2 4 9 1011 vg
1:10 8 9 1010 vg
1:50 1.6 9 1010 vg
1:100 8 9 109 vg
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established autoimmunity after onset of the
disease, a group of 8-week-old mice (n = 5) was
intrathymically injected with AAV9-AIRE
1.6 9 1010 vg per mouse. Control groups were
injected either with PBS or with AAV9-GFP. At
4 weeks postinjection, circulating autoantibodies
against retina, lung, stomach, testis and ovary
were detected in Aire/ mice injected with PBS
and Aire/ mice injected with AAV9-GFP
(Figure 8; n = 5). At 12 weeks of age, serum
autoantibodies were found against 1 or 2 tissues
per mouse in the investigated tissues. At this later
stage of the disease, mice injected with AAV9-
AIRE or AAV9-GFP showed a similar pattern of
reactive autoantibodies. Serum autoantibodies
from these mice showed reactivity to several
tissues including retina, lung, stomach, testis and
ovary of control mice (Figure 9; n = 5), suggesting
the disease needs to be targeted early with this
approach. Correlation of serum autoantibodies
and infiltrations into retina, lung, stomach,
pancreas and ovary/testis tissues is summarised in
Figure 10. The latter showed strong correlation
between the presence of serum autoantibodies
and tissue infiltration. There was no difference
between mice treated with AAV9-AIRE or AAV9-
GFP in terms of circulating autoantibodies and
lymphatic tissue infiltration, suggesting that
AAV9-AIRE treatment has no significant effect on
Aire/ 12-week-old mice (Figure 10).
DISCUSSION
Direct injection of AAV9-AIRE into 4-week-old
AIRE KO mice leads to the clearance of circulating
autoantibodies and reduced T-cell infiltration into
tissues of these mice. The main rationale behind
the choice of AAV9 rather than other serotype is
the fact AAV9 has an established clinical and
safety profile. Indeed, AAV9 has been used for
other clinical trials showing remarkable safety and
efficacy outcomes (e.g. spinal muscular
atrophy).31,33
This proof-of-concept efficacy study has
demonstrated that a noninvasive procedure of
gene delivery with an ultrasound imaging
technique is efficient in targeting AIRE to the
medulla of the thymus. This is important because
(a)
(d) (e)
(b) (c)
Figure 3. Representative images of transduced thymi of 8-week-old APS-1 mice. Aire/ mice were injected at 4 weeks old either with PBS, with
AAV9-GFP or with AAV9-AIRE. Thymi were extracted at 4 weeks postinjection. Thymic sections from mice injected with PBS were labelled with a
keratin 5 antibody shown in red colour (a). Thymic sections from mice injected with AAV9-GFP were stained with a GFP antibody (b) or AIRE
antibody (c). Thymic sections from mice injected with AAV9-AIRE were double-stained with AIRE antibody (green colour) and K5 antibody (red
colour) (d). A positive control with staining of thymic sections from wild-type mice with AIRE antibody (green colour) and K5 antibody (red
colour) (e). Primary antibodies coupled to Alexa Fluor 488 secondary antibody and counterstained with DAPI for visualisation of nuclei. AAV9,
adeno-associated virus serotype 9; AIRE, autoimmune regulator; DAPI, diamidino-2-phenylindole (blue); GFP, green fluorescent protein; PBS,
phosphate-buffered saline. Scale bar = 100 lm in a, 100 lm in b, 100 lm in c, 50 lm in d and 100 lm in e.
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it avoids expressing AIRE in thymic epithelium
cells which lead to autoimmunity45. This study
also showed that 4 weeks post-intrathymic
injections of AAV9-AIRE in Aire/ mice, mRNA
encoding AIRE and Aire-dependent TSAs were
significantly elevated. Correspondingly, following
AIRE expression, serum autoantibodies levels were
reduced 4 weeks postinjection. The novel
molecular therapy approach employed led to an
ameliorated autoimmunity phenotype in APS-1
mouse model.
Modulation of AIRE in vivo can directly lead to
alterations in TSA levels and may affect the
maintenance of central tolerance. To confirm that
thymic expression of TSAs does affect self-
tolerance, serum autoantibodies from AAV9-AIRE-
injected mice were screened for autoreactivity
against several tissues including retina, lung,
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Figure 4. Aire-dependent and Aire-independent tissue-specific antigen (TSA) expression after viral delivery of AIRE in vivo in APS-1 mice.
Quantitative PCR analysis of Aire/AIRE expression and Aire-dependent including Ins2, Spt1 and Apoa1 (a) and Aire-independent including Cpox,
Ncoa6 and Ppib (b) TSAs in thymic cells obtained at 4 weeks postinjection from Aire+/+ mice (n = 5), Aire/ mice (n = 5), Aire/ AAV9-GFP
mice (n = 5) and Aire/ AAV9-AIRE-injected mice (n = 5). Data are normalised to the expression of b-actin and are presented relative to the
expression values in Aire/ thymic cells. Data are analysed with one-way ANOVA, Tukey’s multiple comparison test, ****P < 0.0001,
**P < 0.005, *P ≤ 0.05. Error bars represent  SEM. Aire, murine autoimmune regulator; AIRE, human autoimmune regulator; Apoa1,
apolipoprotein A-I; Cpox, coproporphyrinogen oxidase; Ins2, insulin II; Ncoa6, nuclear receptor coactivator 6; Ppib, peptidylprolyl isomerase B;
Spt1, salivary protein 1. Aire/ mice expressed Aire mRNA, but the produced protein is nonfunctional.18
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pancreas, stomach, ovary and testis.18,37 The
investigated sera harboured no autoantibodies
against the key tissues. In addition, histological
analysis of Aire/ treated with AAV9-AIRE
revealed no tissue infiltrations at all. Thus, the
expected disease phenotype was ameliorated
when compared to the autoimmunity profile of
Aire/ mice and AAV9-GFP-injected Aire/ mice.
Several studies have reported that Aire
promotes the generation of a distinct repertoire
Aire
+/+
Aire
–/–
Aire
–/–
AAV9-AIREAire
–/–
AAV9-GFP(a) (b)
Figure 5. Representative serum autoantibodies in Aire+/+, Aire/, Aire/ AAV9-GFP and Aire/ AAV9-AIRE mice (8 weeks old). Serum was
collected from Aire+/+ mice (n = 5), Aire/mice (n = 5), Aire/ AAV9-GFP mice (n = 5) and Aire/ AAV9-AIRE mice (n = 5) at 4 weeks
postinjection. Tissues including retina, lung, stomach, pancreas, testis and ovary were obtained from healthy 8-week-old Aire+/+ mice. Sections
were incubated with individual mouse serum. Nuclei were counterstained with DAPI. AAV9, adeno-associated virus serotype 9; AIRE, autoimmune
regulator; DAPI, diamidino-2-phenylindole (blue). Scale bar 100 lm.
Figure 6. Representative tissue sections from 8-week-old APS-1 mice. Retina, lung, liver and stomach sections from Aire+/+, Aire/, Aire/
AAV9-GFP and Aire/ AAV9-AIRE mice, stained with haematoxylin and eosin (H&E). Arrowhead indicates infiltration. Scale bar: retina, 100 lm;
liver, 500 lm; lung, stomach, ovary and testis, 250 lm.
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of Treg during the perinatal period that stably
persists in adult mice.46–48 When Aire was turned
on by doxycycline during the neonatal period up
to 3 weeks after birth and then turned off, these
mice were protected from autoimmunity.46
Following this, several investigations led to the
discovery of a distinct subset of Treg produced
during the perinatal window and this population
has a role in maintaining self-tolerance unique
from those of Treg repertoire produced during
adulthood.47,48 This highlights the importance of
Aire expression early in life in order to maintain
long-term self-tolerance. However, the
overexpression of AAV9 Aire after the perinatal
window and during adulthood seems to be
essential to produce a Treg repertoire that could
ameliorate autoimmunity.
Our molecular therapy study shows that AIRE
was expressed in the medulla of thymus. The
question that arises as a result is what cells within
the thymus are the ultimate targets of AAV9 and
which of these drive long-term expression of the
transgene? We suggest that mTEC cells are
targeted by AAV9 and that the use of AIRE
promoter would restrict AIRE expression to these
cells. This approach would be challenging because
tissue-specific expression of AIRE is exclusively
controlled by an upstream enhancer region.49,50 A
potential limitation in translating our findings is
that mTEC cells are short-lived with estimated
Figure 7. Correlation of serum autoantibodies and tissue infiltrations in 8-week-old groups of APS-1 mouse model (8 weeks old). For each
mouse of the indicated group AAV9 virus and gender, the presence (shaded) or absence of autoantibodies against retina, lung, stomach,
pancreas and ovary/testis is displayed. An asterisk indicates tissue infiltration.
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lifespan of 2–3 days, and since AAV is a
nonintegrating vector, the expression and
negative T-cell selection occurring after
transduction would be transient. However, our
data suggest that transient expression of AIRE in
mTEC would be sufficient to confer benefit to
patients even if AAV9-encoded AIRE was
expressed transiently and if the disease is targeted
early. We propose therefore from our data that
there would be specific benefit for paediatric
patients since we were able to rescue the AIRE-
deficient phenotype in the early phase of the
disease versus later time points. This could be
because the subset of Treg cells that protect the
organism against potential immune attack is
produced early in life, during the perinatal
window. Thus, a molecular therapy approach
could offer a potential treatment for APS-1
patients at early age of onset of the disease.
Based on the promising data obtained in our
proof-of-concept preclinical study, we plan to take
our gene therapy approach towards translational
path by completing the following tasks: (1)
generation of the final configuration of the
therapeutic vector; (2) preparation of preclinical
safety package and clinical design for discussion
with regulators; (3) complete GMP manufacturing
of clinical-grade vector for use in clinical trials; and
(4) prepare clinical trial application (CTA).
METHODS
Mice
B6.129S2-Airetm1.1Doi/J were purchased from the Jackson
Laboratory (004743) (The Jackson Laboratory, Bar Harbor,
ME, USA). Aire/mice carry a deletion of exon 2 which
causes frame shift and gives an early truncated Aire protein
at amino acid 48 out of 545.18 All mice were maintained in
Aire–/– AAV9-AIRE Aire–/– AAV9-GFP
Figure 8. Representative serum autoantibodies in Aire+/+, Aire/, Aire/ AAV9-GFP and Aire/ AAV9-AIRE mice (16 weeks old). Serum was
collected from Aire+/+ mice (n = 5), Aire/mice (n = 5), Aire/ AAV9-GFP mice (n = 5) and Aire/ AAV9-AIRE mice (n = 5) 4 weeks
postinjection. Tissues including retina, lung, stomach, pancreas, testis and ovary were obtained from healthy 8-week-old Aire+/+ mice. Sections
were incubated with individual mouse serum. Nuclei were counterstained with DAPI. AAV9, adeno-associated virus serotype.
2020 | Vol. 9 | e1166
Page 10
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology, Inc.
AAV9-AIRE transfer in experimental APS-1 S Almaghrabi et al.
a controlled facility in a 12-h dark–light photocycle with
free access to food and water and maintained in a specific
pathogen-free animal facility.
AAV9-AIRE viral vector production
Single-stranded AAV (ssAAV) expressing human AIRE cDNA
was constructed by ligation of the human AIRE cDNA
polymerase chain reaction (PCR) product (forward primer:
50-GATGCCGCTAGCGCCGCCACCATGGCGA-30; reverse primer:
50-CCGGCCAAGCTTGGGCCCTCAATGATG-30). NOTE: this was
amplified from a previously cloned plasmid in our
laboratory. The human AIRE shares 89% amino acid identity
with murine Aire. The full CMV promoter was derived from
pAAV-MCS (Stratagene, Stockport, UK). The GFP cDNA of
the AAV9-GFP plasmid was replaced with the AIRE cDNA
PCR product. Standard cloning procedures for DNA
extraction and production of the large-scale plasmids were
followed using QIAGEN kits following the manufacturer’s
instructions. High-titre scAAV9 vectors were then prepared
using a three-plasmid transient cotransfection system.
HEK293T cells in 15-cm dishes were transfected with
packaging plasmids pHelper (Stratagene), pAAV2/9 and the
transgene vector ssAAV-AIRE at 2:1:1 ratio, respectively,
using polyethylenimine (1 mg mL1) in serum-free
Dulbecco’s modified Eagle’s medium (DMEM). At 5 days
post-transfection, supernatant containing cell-released virus
was harvested, treated with benzonase (10 unit mL1;
Sigma, Poole, UK) for 2 h at 37°C and concentrated to
equal approximately 24 mL using Amicon Ultra-15
Centrifugal 100K Filters (Millipore, Watford, UK). Iodixanol
gradient containing 15%, 25%, 40% and 54% iodixanol
solution in phosphate-buffered saline (PBS)/1 mmol L1
MgCl2/2.5 mmol L
1 KCl and virus solution was loaded and
centrifuged at 69 000 revolutions per minute for 90 min at
18°C. After ultracentrifugation, the virus fractions were
visualised on a 10% polyacrylamide gel, stained using
SYPRO Ruby (Life Technologies, Paisley, UK) according to
the manufacturer’s guidelines. The highest purity fractions
(identified by the presence of the three bands
corresponding to VP1, VP2 and VP3) were pooled and
concentrated further in the final formulation buffer
consisting of PBS supplemented with an additional
35 mmol L1 NaCl using Amicon Ultra-15 Centrifugal 100K
Filters. Viral titres were determined by quantitative PCR
assays using primers directed against AIRE and a linearised
ssAAV-CMV-AIRE vector as a standard curve.
Intrathymic injections
Ultrasound imaging of the thymus
To avoid using procedures that require opening the thorax
and to improve success rates with noninvasive procedures,
ultrasound imaging technique51,52 was adopted for
accurately locating the thymus in anaesthetised 4-week-old
mice. To validate this technique, ten 4-week-old Aire mice
were used. Using the Vevo 770 (VisualSonics, Toronto,
Canada) preclinical scanner, the thymus of 4-week Aire mice
could easily be visualised. Syringe needle within the thymus
was detected by the ultrasound imaging system. Four
groups of mice were recruited: Aire+/+ mice were injected
with PBS (n = 5), Aire/ were injected with PBS (n = 5),
Aire/ mice were injected with AAV9-GFP (n = 5), and
Aire/ mice were injected with AAV9-AIRE (n = 5).
Serum autoantibody screening
Mice were killed at 4 weeks post-vector delivery.
Designated tissues were removed, fixed in 4% PFA and
embedded in paraffin. Tissue sections were stained with
Figure 9. Representative tissue sections from 16-week-old APS-1 mice. Retina, lung, liver and stomach sections from Aire+/+, Aire/, Aire/
AAV9-GFP and Aire/ AAV9-AIRE mice, stained with haematoxylin and eosin (H&E). Arrowhead indicates infiltration. Scale bar: retina, 100 lm;
liver, 500 lm; lung, stomach, ovary and testis, 250 lm.
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H + E, and infiltration of various organs was scored. The
detection of autoAbs was monitored. Briefly, serum was
collected from Aire+/+ mice injected with PBS, Aire/
injected with PBS, Aire/ mice injected with AAV9-GFP and
Aire/ mice injected with AAV9-AIRE. Tissues including
retina, lung, stomach, pancreas, testis and ovary were
obtained from healthy 8-week-old Aire+/+ mice. Sections
were incubated with individual mouse serum. Serums and
tissue sections from each animal were anonymously coded
to allow blinded accession of each animal.
Histological analysis
Tissue collection
Mice were euthanised by intraperitoneal injection of
500 mg kg1 of sodium pentobarbital (sodium
pentobarbital, 20% w/v solution for injections, JML). Tissues
were collected and immediately fixed by 4%
paraformaldehyde (4% PFA) overnight at 4°C. The tissues
were then transferred to PBS, paraffin-embedded and
sectioned at 5 µm. To analyse AAV9-GFP transduction
efficiency, tissues were embedded in OCT and frozen at
80°C. After sectioning, 1 in 10 slides were taken
throughout each tissue for analysis. Sections were
incubated in xylene twice for 10 min before being hydrated
through 100%, 95% and 70% ethanol. After blocking
endogenous peroxidase activity and antigen retrieval,
sections were incubated with protein block serum-free
(DAKO) for 10 min to block any nonspecific binding. After
tissue permeabilisation with 0.3% Triton X-100, sections
were incubated with a polyclonal goat antibody against
Aire D-17 (sc-17986; Santa Cruz Biotechnology, Heidelberg,
Germany) at dilution of 1:50 in 0.15% Triton X-100 in PBS
for 1 hr at room temperature. For serum autoantibody
analysis in mouse injected with AAV9-AIRE, mouse serum
was tested using 4% fixed tissue sections from healthy mice
by indirect immunofluorescence. We used 15 tissue sections
analysed per tissue per animal. For GFP visualisation, AAV9-
Figure 10. Correlation of serum autoantibodies and tissue infiltrations in 8-week-old groups of APS-1 mouse model (16 weeks old). For each
mouse of the indicated group AAV9 virus and gender, the presence (shaded) or absence of autoantibodies against retina, lung, stomach,
pancreas and ovary/testis is displayed. An asterisk indicates tissue infiltration.
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GFP thymic sections were fixed with acetone for 20 min
and mounted using VECTASHIELD Antifade Mounting
Medium with DAPI (Vector Lab, Burlingame, CA, USA).
Images were taken with fluorescence microscope (Leica
AF6000).
Quantitative PCR
Total RNA was extracted using the TRI Reagent (Sigma-
Aldrich, Dorset, UK). Tissues were homogenised using
mortar and pestle with liquid nitrogen. TRI Reagent was
added on the powdered tissues and transferred into 1.5-mL
Eppendorf tubes for subsequent phase separation. The
aqueous phase containing the RNA was separated and
transferred to a fresh tube, and then, the RNA was
precipitated by adding 0.5 mL of isopropanol per 1 mL of
TRI Reagent. Pelleted RNA was then washed with 75%
ethanol and resuspended in 30 lL of RNase-free water. RNA
concentration was measured by NanoDrop. RNA was
reverse-transcribed, and cDNA was synthesised using
SuperScript IV First-Strand Synthesis System Kit by random
hexamer (18091050; Invitrogen, Paisley; UK) according to
the manufacturer’s protocol. Samples were used for
quantitative RT-PCR (qPCR). qPCR, consisted of 10 lL power
SYBRTM Green PCR Master Mix (4367659; Applied Biosystems,
Paisley, UK), cDNA and 600 nM forward and reverse primers
(Supplementary table 1) to a total volume of 20 lL, was run
in triplicate. The PCR was carried out in 384-well plate
using 7900HT Real-Time PCR System (Applied Biosystems).
Western blots
Cells were washed with cold PBS and pelleted in 1.5-mL
Eppendorf tubes before adding the
radioimmunoprecipitation assay (RIPA) buffer which is
composed of 50 mM Tris-HCl pH 7.4 (Sigma-Aldrich), 150 mM
NaCl (Sigma-Aldrich), 2 mM (ethylenediaminetetraacetic
acid) EDTA, 1% Triton X-100 (Sigma-Aldrich), 0.5% sodium
deoxycholate and 0.1% sodium dodecyl sulphate (SDS)
(Sigma-Aldrich), supplemented with 1% protease inhibitor
cocktail (Sigma-Aldrich). Briefly, the cell pellet was
suspended in 200–500 lL of RIPA and incubated for 20 min
on ice to lyse the cells. The lysates were centrifuged at
13 000 g and 4°C for 10 min, and then, the supernatant
containing the protein was separated from cell debris and
collected into a labelled 1.5-mL Eppendorf tube. Before
loading the protein, samples were denatured by heating at
95°C for 5 min with Laemmli buffer (Sigma-Aldrich) and
then loaded onto a 10% SDS-PAGE gel. The gels were
electrophoresed in Tris/glycine/SDS running buffer at 60 V
for 20 min and then 60–90 min at 120 V. For
immunodetection, proteins were transferred onto a PVDF
membrane (Millipore). The PVDF membrane was soaked in
100% methanol before being immersed in cold transfer
buffer. The proteins were transferred onto the PVDF
membrane in transfer buffer at 250 mA for 1 h. Membranes
were then blocked in 5% milk TBS-T blocking buffer for
60 min at room temperature in a roller (Milton). Primary
and secondary antibody solutions were prepared in 5%
milk TBS-T blocking buffer. Goat primary antibody against
AIRE (sc-17986; Santa Cruz Biotechnology) was diluted at
1:2500, and rabbit primary antibodies against b-actin
(ab49900, Abcam; Cambridge, UK) and GAPDH (ab181602;
Abcam) were diluted at 1:3000 and 1:10 000, respectively.
All primary antibodies were incubated at 4°C overnight
with agitation. HRP (horseradish peroxidase) secondary
antibodies, anti-goat HRP antibody (P0160; DAKO, Ely, UK)
and anti-rabbit HRP antibody (7074S; Cell Signalling), were
used at a dilution of 1:5000 and 1:10 000, respectively,
incubated for 1 h at room temperature in a roller (Milton).
Between the primary and secondary antibody incubations,
the membranes were washed three times for 10 min in TBS-
T at room temperature in the roller (Milton) to remove any
unbound antibodies. The proteins were visualised using the
ECL Plus Chemiluminescence Detection Kit (GE Healthcare,
Little Chalfont, UK) for HRP. The chemiluminescence was
visualised using the G:BOX Image Capture System (G:BOX;
Syngene).
Statistical analysis
All the data shown in the present study are reported as
means  SEM. The number of sampled units, n, upon which
we reported statistic, is the single mouse for the in vivo
experiments (one mouse is n = 1). GraphPad Prism 6
software (GraphPad Software) was used for statistical
analyses. P < 0.05 was considered significant. For all the
data sets, data were analysed by parametric tests, a = 0.05
(one-way ANOVA with Tukey’s post hoc test). The statistical
analysis performed for each data set as compared to
untreated controls is indicated in figure captions. For all
figures, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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